Clinical Trials and Regulatory Approvals
Essential for drug commercialization
- Materiality
- high
BioArctic
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company is renowned for Leqembi, a groundbreaking drug that slows the progression of early Alzheimer's disease, developed in collaboration with Eisai. BioArctic leverages its proprietary BrainTransporter technology to enhance drug delivery to the brain. The company is listed on Nasdaq Stockholm Large Cap and is committed to sustainable growth through strategic partnerships and cutting-edge research.
131
4.78
4.21
| % | |
|---|---|
| Alzheimer's Treatments | 50% Includes drugs like Leqembi for Alzheimer's disease |
| Parkinson's and ALS Treatments | 20% Drug candidates for Parkinson's and ALS |
| BrainTransporter Technology | 15% Technology for enhanced drug delivery to the brain |
| Licensing and Partnerships | 15% Revenue from licensing and commercialization deals |
BioArctic's customer base primarily includes large pharmaceutical companies and healthcare providers...
- Pharmaceutical Companiesprimary
Purchase and co-develop innovative treatments for neurodegenerative diseases
- Healthcare Providerssecondary
Implement treatments to improve patient care in neurology
- Research Institutionsemerging
Collaborate on drug development and clinical trials
BioArctic is headquartered in Stockholm, Sweden, with operations extending across the Nordic region through...
- •Headquartered in Stockholm, Sweden
- •Operations in Denmark, Finland, and Norway
- •Focus on Nordic market for initial drug launches
- •Partnerships extend reach to US, EU, Japan, and China
- •Strategic expansion plans into Europe
BioArctic's strategic priorities include accelerating innovation, expanding its drug pipeline, and forming strategic...
01
Accelerate Innovationmedium-term
To develop cutting-edge treatments for severe brain diseases
02
Expand Drug Pipelinelong-term
To ensure a balanced and comprehensive portfolio
03
Form Strategic Partnershipsshort-term
To enhance global reach and commercialization
BioArctic faces several risks, including dependency on successful clinical trials and regulatory approvals, which are...
Partnership Dependency
Financial and developmental reliance on partners
- Materiality
- high
Revenue Fluctuations
Irregular milestone payments and royalties
- Materiality
- medium
Revenue Recognition
Significant on financial analysis
Licensing Agreements
Affects revenue timing
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
BIOVIE INC.
BIVI · Pharmaceutical Preparations
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
BioAge Labs, Inc.
BIOA · Pharmaceutical Preparations
BIOGEN INC.
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
Alector, Inc.
ALEC · Biological Products, (No Diagnostic Substances)
: 11/08/2026